Post hoc analysis of a phase 2 SLE trial (363 patients, 56 healthy volunteers): whole blood RNA-seq showed deucravacitinib modulated up to 2529 genes, including interferon-regulated genes, reduced plasma cell gene sets and normalised myeloid gene sets.
Secondary analysisn = 363
Vital et al. Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial